Global health impact: A basis for labeling and licensing campaigns?

Developing World Bioethics 12 (3):121-134 (2012)
  Copy   BIBTEX

Abstract

Most of the world's health problems afflict poor countries and their poorest inhabitants. There are many reasons why so many people die of poverty-related causes. One reason is that the poor cannot access many of the existing drugs and technologies they need. Another, is that little of the research and development (R&D) done on new drugs and technologies benefits the poor. There are several proposals on the table that might incentivize pharmaceutical companies to extend access to essential drugs and technologies to the global poor.1 Still, the problem remains – the poor are suffering and dying from lack of access to essential medicines. So, it is worth considering a new alternative. This paper suggests rating pharmaceutical and biotechnology companies based on how some of their policies impact poor people's health. It argues that it might be possible to leverage a rating system to encourage companies to extend access to essential drugs and technologies to the poor

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 90,221

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Corporate Responsibilities for Access to Medicines.Klaus M. Leisinger - 2009 - Journal of Business Ethics 85 (S1):3 - 23.

Analytics

Added to PP
2012-02-08

Downloads
55 (#258,576)

6 months
2 (#658,980)

Historical graph of downloads
How can I increase my downloads?

Author's Profile

Nicole Hassoun
State University of New York at Binghamton

References found in this work

No references found.

Add more references